Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Jeffrey R. STRAWN |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
Commentary: Treatment failure and success: a commentary on defining and treating pediatric treatment-resistant depression - reflections on Dwyer et al. (2020) / Jeffrey R. STRAWN in Journal of Child Psychology and Psychiatry, 61-3 (March 2020)
[article]
Titre : Commentary: Treatment failure and success: a commentary on defining and treating pediatric treatment-resistant depression - reflections on Dwyer et al. (2020) Type de document : Texte imprimé et/ou numérique Auteurs : Jeffrey R. STRAWN, Auteur ; Paul E. CROARKIN, Auteur Article en page(s) : p.333-335 Langues : Anglais (eng) Mots-clés : Depression major depressive disorder treatment-resistant depression Index. décimale : PER Périodiques Résumé : Nearly two in five youth with major depressive disorder fail to respond to first-line interventions. As such, treatment-resistant depression represents a formidable challenge for clinicians and researchers. In fact, even considering the diagnosis of treatment-resistant depression in children and adolescents requires (a) defining treatment-resistant depression and, by extension, treatment failure; (b) defining recovery; (c) understanding its developmental trajectory; and in addition to (d) understanding the evidence for treatment interventions in this population. Accumulating data suggest that treatment-resistant depression is heterogeneous and that this heterogeneity may inform interventions. Additionally, these data suggest that substantially more nuance is needed in evaluating the 'adequacy' of prior treatments whether they are psychotherapeutic or psychopharmacologic. Last, adjunctive interventions that focus on neuromodulation, glutamatergic, GABAergic, and inflammatory pathways remain poorly understood in youth with treatment-resistant depression despite very significant advances in adults with treatment-resistant depression. En ligne : http://dx.doi.org/10.1111/jcpp.13207 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420
in Journal of Child Psychology and Psychiatry > 61-3 (March 2020) . - p.333-335[article] Commentary: Treatment failure and success: a commentary on defining and treating pediatric treatment-resistant depression - reflections on Dwyer et al. (2020) [Texte imprimé et/ou numérique] / Jeffrey R. STRAWN, Auteur ; Paul E. CROARKIN, Auteur . - p.333-335.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 61-3 (March 2020) . - p.333-335
Mots-clés : Depression major depressive disorder treatment-resistant depression Index. décimale : PER Périodiques Résumé : Nearly two in five youth with major depressive disorder fail to respond to first-line interventions. As such, treatment-resistant depression represents a formidable challenge for clinicians and researchers. In fact, even considering the diagnosis of treatment-resistant depression in children and adolescents requires (a) defining treatment-resistant depression and, by extension, treatment failure; (b) defining recovery; (c) understanding its developmental trajectory; and in addition to (d) understanding the evidence for treatment interventions in this population. Accumulating data suggest that treatment-resistant depression is heterogeneous and that this heterogeneity may inform interventions. Additionally, these data suggest that substantially more nuance is needed in evaluating the 'adequacy' of prior treatments whether they are psychotherapeutic or psychopharmacologic. Last, adjunctive interventions that focus on neuromodulation, glutamatergic, GABAergic, and inflammatory pathways remain poorly understood in youth with treatment-resistant depression despite very significant advances in adults with treatment-resistant depression. En ligne : http://dx.doi.org/10.1111/jcpp.13207 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420 Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years? / Jeffrey R. STRAWN in Journal of Child Psychology and Psychiatry, 62-2 (February 2021)
[article]
Titre : Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years? Type de document : Texte imprimé et/ou numérique Auteurs : Jeffrey R. STRAWN, Auteur ; Lu LU, Auteur ; Tara S. PERIS, Auteur ; Amir LEVINE, Auteur ; John T. WALKUP, Auteur Année de publication : 2021 Article en page(s) : p.114-139 Langues : Anglais (eng) Mots-clés : Generalized anxiety disorder Sri) fMRI pharmacogenomics selective serotonin reuptake inhibitor (SSRI separation anxiety disorder Index. décimale : PER Périodiques Résumé : BACKGROUND: Anxiety disorders first emerge during the critical developmental periods of childhood and adolescence. This review synthesizes recent findings on the prevalence, risk factors, and course of the anxiety disorders; and their neurobiology and treatment. METHODS: For this review, searches were conducted using PubMed, PsycINFO, and clinicaltrials.gov. Findings related to the epidemiology, neurobiology, risk factors, and treatment of pediatric anxiety disorders were then summarized. FINDINGS: Anxiety disorders are high prevalence, and early-onset conditions associated with multiple risk factors including early inhibited temperament, environment stress, and structural and functional abnormalities in the prefrontal-amygdala circuitry as well as the default mode and salience networks. The anxiety disorders are effectively treated with cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). CONCLUSIONS: Anxiety disorders are high prevalence, early-onset conditions associated with a distinct neurobiological fingerprint, and are consistently responsive to treatment. Questions remain regarding who is at risk of developing anxiety disorders as well as the way in which neurobiology predicts treatment response. En ligne : http://dx.doi.org/10.1111/jcpp.13262 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=440
in Journal of Child Psychology and Psychiatry > 62-2 (February 2021) . - p.114-139[article] Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years? [Texte imprimé et/ou numérique] / Jeffrey R. STRAWN, Auteur ; Lu LU, Auteur ; Tara S. PERIS, Auteur ; Amir LEVINE, Auteur ; John T. WALKUP, Auteur . - 2021 . - p.114-139.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 62-2 (February 2021) . - p.114-139
Mots-clés : Generalized anxiety disorder Sri) fMRI pharmacogenomics selective serotonin reuptake inhibitor (SSRI separation anxiety disorder Index. décimale : PER Périodiques Résumé : BACKGROUND: Anxiety disorders first emerge during the critical developmental periods of childhood and adolescence. This review synthesizes recent findings on the prevalence, risk factors, and course of the anxiety disorders; and their neurobiology and treatment. METHODS: For this review, searches were conducted using PubMed, PsycINFO, and clinicaltrials.gov. Findings related to the epidemiology, neurobiology, risk factors, and treatment of pediatric anxiety disorders were then summarized. FINDINGS: Anxiety disorders are high prevalence, and early-onset conditions associated with multiple risk factors including early inhibited temperament, environment stress, and structural and functional abnormalities in the prefrontal-amygdala circuitry as well as the default mode and salience networks. The anxiety disorders are effectively treated with cognitive behavioral therapy (CBT), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). CONCLUSIONS: Anxiety disorders are high prevalence, early-onset conditions associated with a distinct neurobiological fingerprint, and are consistently responsive to treatment. Questions remain regarding who is at risk of developing anxiety disorders as well as the way in which neurobiology predicts treatment response. En ligne : http://dx.doi.org/10.1111/jcpp.13262 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=440